137 related articles for article (PubMed ID: 14623063)
1. Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover.
Uemura H; Yasui T; Umino Y; Niki H; Takikawa M; Saito S; Furumoto H; Irahara M
Bone; 2003 Nov; 33(5):860-6. PubMed ID: 14623063
[TBL] [Abstract][Full Text] [Related]
2. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
Rogers A; Saleh G; Hannon RA; Greenfield D; Eastell R
J Clin Endocrinol Metab; 2002 Oct; 87(10):4470-5. PubMed ID: 12364420
[TBL] [Abstract][Full Text] [Related]
3. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin and bone mineral density in hemodiafiltration patients.
Crisafulli A; Romeo A; Floccari F; Aloisi E; Atteritano M; Cincotta M; Aloisi C; Pizzoleo MA; Ruello A; Artemisia A; Valenti A; Frisina N; Teti D; Buemi M
Ren Fail; 2005; 27(5):531-9. PubMed ID: 16152990
[TBL] [Abstract][Full Text] [Related]
5. Correlates of osteoprotegerin levels in women and men.
Khosla S; Arrighi HM; Melton LJ; Atkinson EJ; O'Fallon WM; Dunstan C; Riggs BL
Osteoporos Int; 2002 May; 13(5):394-9. PubMed ID: 12086350
[TBL] [Abstract][Full Text] [Related]
6. Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers.
Uemura H; Yasui T; Kiyokawa M; Kuwahara A; Ikawa H; Matsuzaki T; Maegawa M; Furumoto H; Irahara M
J Endocrinol; 2002 Aug; 174(2):353-9. PubMed ID: 12176675
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
Valero C; Olmos JM; Rivera F; Hernández JL; Vega ME; Macías JG
Calcif Tissue Int; 2006 Jun; 78(6):343-7. PubMed ID: 16830204
[TBL] [Abstract][Full Text] [Related]
8. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
[TBL] [Abstract][Full Text] [Related]
9. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis.
Grigorie D; Neacşu E; Marinescu M; Popa O
Rom J Intern Med; 2003; 41(4):409-15. PubMed ID: 15526523
[TBL] [Abstract][Full Text] [Related]
10. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.
Fahrleitner A; Prenner G; Leb G; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Portugaller HR; Berghold A; Dobnig H
Bone; 2003 Jan; 32(1):96-106. PubMed ID: 12584041
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.
Fahrleitner-Pammer A; Dobnig H; Piswanger-Soelkner C; Bonelli C; Dimai HP; Leb G; Obermayer-Pietsch B
Wien Klin Wochenschr; 2003 May; 115(9):291-7. PubMed ID: 12793029
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status.
Szulc P; Hofbauer LC; Heufelder AE; Roth S; Delmas PD
J Clin Endocrinol Metab; 2001 Jul; 86(7):3162-5. PubMed ID: 11443182
[TBL] [Abstract][Full Text] [Related]
13. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients.
Mesquita M; Wittersheim E; Demulder A; Dratwa M; Bergmann P
Adv Perit Dial; 2005; 21():181-4. PubMed ID: 16686314
[TBL] [Abstract][Full Text] [Related]
14. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.
Indridason OS; Franzson L; Sigurdsson G
Osteoporos Int; 2005 Apr; 16(4):417-23. PubMed ID: 15776220
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients.
Haas M; Leko-Mohr Z; Roschger P; Kletzmayr J; Schwarz C; Domenig C; Zsontsich T; Klaushofer K; Delling G; Oberbauer R
Am J Kidney Dis; 2002 Mar; 39(3):580-6. PubMed ID: 11877577
[TBL] [Abstract][Full Text] [Related]
16. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
[TBL] [Abstract][Full Text] [Related]
17. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
18. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.
Yano K; Tsuda E; Washida N; Kobayashi F; Goto M; Harada A; Ikeda K; Higashio K; Yamada Y
J Bone Miner Res; 1999 Apr; 14(4):518-27. PubMed ID: 10234572
[TBL] [Abstract][Full Text] [Related]
19. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
20. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
Marshall LA; Cain DF; Dmowski WP; Chesnut CH
Obstet Gynecol; 1996 Mar; 87(3):350-4. PubMed ID: 8598953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
